PHARMAC have announced CGM funding for people with Type 1 diabetes from 1 October 2024. More detail to come.Additional information on Diabetes New Zealand website and the Pharmac Websites
You have nothing in your cart.
If you know the product code enter it here
If you know the product code enter it into the search field
Recombinant Human CXCL1 (GRO-α) (carrier-free), 10 μg
Recombinant Human CXCL1 (GRO-α) (carrier-free), 100 μg
Recombinant Human CXCL1 (GRO-α) (carrier-free), 25 μg
Recombinant Human CXCL1 (GRO-α) (carrier-free), 500 μg
Recombinant Human CXCL10 (IP-10) (carrier-free), 10 μg
Recombinant Human CXCL10 (IP-10) (carrier-free), 100 μg
Recombinant Human CXCL10 (IP-10) (carrier-free), 25 μg
Recombinant Human CXCL10 (IP-10) (carrier-free), 500 μg
Recombinant Human CXCL11 (ITAC) (carrier-free), 10 μg
Recombinant Human CXCL11 (ITAC) (carrier-free), 100 μg
Recombinant Human CXCL11 (ITAC) (carrier-free), 25 μg
Recombinant Human CXCL11 (ITAC) (carrier-free), 500 μg
Recombinant Human CXCL12 (SDF-1α) (carrier-free), 10 μg
Recombinant Human CXCL12 (SDF-1α) (carrier-free), 100 μg
Recombinant Human CXCL12 (SDF-1α) (carrier-free), 25 μg
Recombinant Human CXCL12 (SDF-1α) (carrier-free), 500 μg